Treatment Resistant Depression Clinical Trial
— PAUSEOfficial title:
Augmenting and Sustaining Electroconvulsive Therapy (ECT) Treatment Effects by Group Cognitive Behavioural Therapy (CBT) in Unipolar Depressed Patients
NCT number | NCT04159285 |
Other study ID # | PAUSE |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 5, 2019 |
Est. completion date | June 15, 2021 |
Verified date | August 2021 |
Source | Charite University, Berlin, Germany |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study aims to investigate effectiveness and feasability of a 15-week group psychotherapeutic intervention as continuation treatment after electroconvulsive therapy in severely depressed patients. Feasibility and acceptance of the half-open manualized CBT intervention are assessed. Depressive symptoms, quality of life and emotion regulation skills will be assessed before ECT treatment, before and after the 15-week group CBT intervention and at a 6 months follow-up after treatment end and compared to depressed patients treated with ECT who did not partake in group CBT. Moreover, patients will attend two indidivual pre-group sessions with one of the group therapist and one individual post-group session
Status | Completed |
Enrollment | 16 |
Est. completion date | June 15, 2021 |
Est. primary completion date | May 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - treated with ECT for major depression Exclusion Criteria: - severe comorbid personality disorders - principal diagnosis other than depression |
Country | Name | City | State |
---|---|---|---|
Germany | Charité | Berlin |
Lead Sponsor | Collaborator |
---|---|
Charite University, Berlin, Germany |
Germany,
Brakemeier EL, Merkl A, Wilbertz G, Quante A, Regen F, Bührsch N, van Hall F, Kischkel E, Danker-Hopfe H, Anghelescu I, Heuser I, Kathmann N, Bajbouj M. Cognitive-behavioral therapy as continuation treatment to sustain response after electroconvulsive therapy in depression: a randomized controlled trial. Biol Psychiatry. 2014 Aug 1;76(3):194-202. doi: 10.1016/j.biopsych.2013.11.030. Epub 2013 Dec 12. Erratum in: Biol Psychiatry. 2014 Sep 1;76(5):430. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Clinican-Rated Depressive Symptoms at treatment end | MADRS | End of group therapy treatment (~6 months after ECT treatment) | |
Primary | Clinican-Rated Depressive Symptoms at follow-up | MADRS | 6 months after end of group therapy | |
Secondary | Quality of life at follow-up | WHOQL-Bref | 6 months after end of group therapy | |
Secondary | Emotion regulation capacities at follow-up | Cognitive Emotion Regulation Questionnaire | 6 months after end of group therapy | |
Secondary | Self-Reported Depressive Symptoms at treatment end | BDI | End of group therapy treatment (~6 months after ECT treatment) | |
Secondary | Self-Reported Depressive Symptoms at follow up | BDI | 6 months after end of group therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04124341 -
PCS in Severe Treatment Resistant Depression
|
N/A | |
Recruiting |
NCT03887715 -
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
|
N/A | |
Completed |
NCT04727229 -
Stellate Ganglion Block for Major Depressive Disorder.
|
Phase 4 | |
Completed |
NCT04634669 -
Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE)
|
Phase 2 | |
Withdrawn |
NCT03175887 -
Investigational TMS Treatment for Depression
|
N/A | |
Completed |
NCT03134066 -
Neurocognitive Features of Patients With Treatment-Resistant Depression
|
||
Active, not recruiting |
NCT01984710 -
Deep Brain Stimulation for Treatment Resistant Depression With the Medtronic Activa PC+S
|
N/A | |
Completed |
NCT01935115 -
Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy
|
Phase 4 | |
Terminated |
NCT01687478 -
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
|
Phase 3 | |
Completed |
NCT00531726 -
Berlin Deep Brain Stimulation Depression Study
|
N/A | |
Recruiting |
NCT04041479 -
Biomarker-guided rTMS for Treatment Resistant Depression
|
Phase 3 | |
Recruiting |
NCT05870540 -
BPL-003 Efficacy and Safety in Treatment Resistant Depression
|
Phase 2 | |
Recruiting |
NCT04959253 -
Psilocybin in Depression Resistant to Standard Treatments
|
Phase 2 | |
Completed |
NCT04856124 -
Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
|
||
Recruiting |
NCT03272698 -
ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression
|
Phase 4 | |
Active, not recruiting |
NCT04451135 -
CET- REM (Correlating ECT Response to EEG Markers)
|
N/A | |
Recruiting |
NCT05680220 -
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
|
N/A | |
Completed |
NCT03288675 -
Stepped Care aiTBS 2 Depression Study (Ghent)
|
N/A | |
Recruiting |
NCT06138691 -
KET-RO Plus RO DBT for Treatment Resistant Depression
|
Phase 1 | |
Terminated |
NCT02675556 -
Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression
|
Phase 1 |